Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Michelle S. DeStefano"'
Publikováno v:
Frontiers in Microbiology, Vol 9 (2018)
The current standard of care therapy for pulmonary Mycobacterium kansasii infection is isoniazid (300 mg/day), rifampin (600 mg/day), and ethambutol (15 mg/kg/day) for 12 months after achieving sputum culture negativity. Rifampin is the key drug in t
Externí odkaz:
https://doaj.org/article/69d6484fc7294b1193160ca1e71e7868
Autor:
Douglas S. Kernodle, Michael H. Cynamon, Hiriam O. Gates, Alexandria D. Allen, Miriam Braunstein, Kyi-Toe Tham, Carolyn M. Shoen, Michelle S. DeStefano, Cynthia C. Hager
Publikováno v:
Vaccines, Vol 1, Iss 1, Pp 34-57 (2013)
Early attempts to improve BCG have focused on increasing the expression of prominent antigens and adding recombinant toxins or cytokines to influence antigen presentation. One such modified BCG vaccine candidate has been withdrawn from human clinical
Externí odkaz:
https://doaj.org/article/aaae56e2959f43f2a7bf99aaa49a9511
Publikováno v:
Open Forum Infectious Diseases. 9
Background Epetraborole (EBO) is a boron-containing oral inhibitor of bacterial leucyl-tRNA synthetase, an essential enzyme in protein synthesis; EBO demonstrates potent activity against nontuberculous mycobacteria. These studies evaluated oral doses
Publikováno v:
Open Forum Infectious Diseases. 9
Background Epetraborole (EBO) is a boron-containing, oral inhibitor of bacterial leucyl-tRNA synthetase, an essential enzyme in protein synthesis; EBO demonstrates potent activity against nontuberculous mycobacteria (NTM). The standard of care therap
Publikováno v:
Open Forum Infectious Diseases. 9
Background Epetraborole (EBO) is a boron-containing, oral inhibitor of bacterial leucyl-tRNA synthetase, an essential enzyme in protein synthesis; EBO demonstrates potent activity against nontuberculous mycobacteria. We evaluated the effects of selec
Publikováno v:
Frontiers in Microbiology
The current standard of care therapy for pulmonary Mycobacterium kansasii infection is isoniazid (300 mg/day), rifampin (600 mg/day), and ethambutol (15 mg/kg/day) for 12 months after achieving sputum culture negativity. Rifampin is the key drug in t
Autor:
Amanda E. Hoffman, Robert P. Doyle, Michelle S. DeStefano, Leann Jade Miles, Carolyn Shoen, Michael H. Cynamon, Tiffany J. Greenfield
Publikováno v:
BioMetals. 28:415-423
The minimal inhibitory concentrations (MICs) of copper and cobalt based dimeric pyrophosphate complexes with capping 1,10-phenanthroline groups on clinical isolates of C. albicans (28 isolates), C. krusei (20 isolates) and C. tropicalis (20 isolates)
Autor:
Michel Ledizet, Karen Anthony, Michael H. Cynamon, Sara Mootien, Paul Kaplan, Michelle S. DeStefano, Kacheong R. Yeung, Oluwatoyin A. Asojo, Carolyn Shoen, Paul A. Aristoff, Raymond A. Koski, Pier F. Cirillo, Yashang Lee
Publikováno v:
Biochemical Pharmacology. 86:222-230
The genus Mycobacterium includes non-pathogenic species such as M. smegmatis, and pathogenic species such as M. tuberculosis, the causative agent of tuberculosis (TB). Treatment of TB requires a lengthy regimen of several antibiotics, whose effective
Autor:
Carolyn M. Shoen, Alex J. Chmielewski, Sharon E. Chase, Tami S. Harpster, Michelle S. DeStefano, Michael H. Cynamon
Publikováno v:
Antimicrobial Agents and Chemotherapy. 44:1458-1462
Previous experiments with rifalazil (RLZ) (also known as KRM-1648) in combination with isoniazid (INH) demonstrated its potential for short-course treatment of Mycobacterium tuberculosis infection. In this study we investigated the minimum RLZ-INH tr
Autor:
Michelle S. DeStefano, Krishnamoorthy Gopinath, Digby F. Warner, Michael H. Cynamon, Carolyn Shoen, Robert P. Doyle, Amanda E. Hoffman
Publikováno v:
European journal of medicinal chemistry. 70
Tuberculosis (TB) causes up to 10 million incident cases worldwide per annum. Multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains are leading factors in the resurgence of TB cases and the need to produce new agents to combat such i